Norges Bank’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-40,457
Closed -$2.34M 2102
2022
Q4
$2.34M Buy
40,457
+14,360
+55% +$887K ﹤0.01% 1946
2022
Q3
$2.45M Hold
26,097
﹤0.01% 1880
2022
Q2
$5.82M Buy
26,097
+1,778
+7% +$595K ﹤0.01% 1733
2022
Q1
$13.4M Buy
24,319
+9,696
+66% +$5.86M ﹤0.01% 1593
2021
Q4
$9.66M Buy
14,623
+3,135
+27% +$2.4M ﹤0.01% 1774
2021
Q3
$9.64M Sell
11,488
-14,962
-57% -$15.2M ﹤0.01% 1778
2021
Q2
$33.6M Buy
26,450
+1,259
+5% +$1.42M 0.01% 1201
2021
Q1
$27.6M Buy
25,191
+24,245
+2,563% +$32M 0.01% 1333
2020
Q4
$1.35M Buy
+946
New +$1.01M ﹤0.01% 1996

Other funds holding CDLX

Norges Bank's CDLX Position: Q1 2023 in Review

Norges Bank sold out of Cardlytics (CDLX) in Q1 2023, closing a stake of 40,457 shares — an estimated $2.34M sold.

Norges Bank first reported a position in CDLX in Q4 2020 and held it in 9 quarters. The position peaked at $33.6M in Q2 2021. 103 funds tracked by Wall St. Rank hold CDLX as of Q1 2023.

  • Norges Bank reported no remaining Cardlytics position as of Q1 2023 after selling out during the quarter.
  • Norges Bank sold 40,457 Cardlytics shares in Q1 2023, an estimated $2.34M.
  • Norges Bank first reported a position in Cardlytics in Q4 2020 and held it in 9 quarters.
  • Norges Bank's Cardlytics position peaked at $33.6M in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Cardlytics as of Q1 2023.

Based on Norges Bank's 13F filing for Q1 2023, filed 15 May 2023.